Return to content in this issue

 

Exacerbation Rate Reduction with Mepolizumab, Stratified by Maintenance OCS Use and Eosinophil Levels. A Post-Hoc Analysis of DREAM and MENSA Studies

Bobolea I1, Bañas D2, Melero C3, de Andrés AI2, Joksaite S2, Sánchez-Herrero G2

1Allergy Section, Severe Asthma Unit. Department of Pulmonology and Allergy, Hospital Clinic Barcelona- Institute for Health Research (IdiBAPS)
2GSK Spain
3Hospital 12 de Octubre Institute for Health Research (i+12), Madrid, Spain

J Investig Allergol Clin Immunol 2022; Vol. 32(2)
doi: 10.18176/jiaci.0714

Key words: Asthma, Eosinophils, Exacerbations, Mepolizumab, OCS (oral corticosteroids)